Endolytix's doors opened with 3 employees on March 3rd, 2020. We first incubated at North Shore InnoVentures in Beverly, MA, just north of Boston. We have since moved into a custom-built facility in Beverly and are growing in all areas of drug development.
Built on the idea of attacking intracellular bacteria as a central tenet of treatment, we integrated mammalian cell targeting as an early starting point.
Endolytix took a biological approach to leverage specificity, catalytic capability, and low anticipated-toxicity relative to xenotropic compounds such as small molecule antibiotics.
